Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascaline Boudou-Rouquette

Showing results (31-40 of 122) with videos related to

Pageof 13
Sort By:
Plos One|June 6, 2012
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinomaOlivier Mir, Romain Coriat, Benoit Blanchet, et al.
Cancer Chemotherapy and Pharmacology|August 24, 2023
Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resectionCléa Tardy, Alicja Puszkiel, Pascaline Boudou-Rouquette, et al.
Clinical Medicine (London, England)|August 3, 2021
Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in ParisCamille Tlemsani, Jennifer Arrondeau, Sixtine De Percin, et al.
Investigational New Drugs|November 1, 2016
Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-oldFrederic Bigot, Pascaline Boudou-Rouquette, Jennifer Arrondeau, et al.
The Journal of Nutrition, Health & Aging|March 22, 2024
Prognostic impact of neurocognitive disorders in older patients with cancer: the ELCAPA prospective cohort studyCatherine Conti, Elena Paillaud, Marie Laurent, et al.
Bulletin Du Cancer|April 23, 2025
[Update of the recommendations for the management and treatment of giant cell bone tumors, on behalf of GroupOS]Pascaline Boudou-Rouquette, Frédérique Larousserie, Valérie Dumaine, et al.
International Journal of Molecular Sciences|January 21, 2023
Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment OptionsCamille Tlemsani, Frédérique Larousserie, Sixtine De Percin, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 7, 2017
Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patientsAlicja Puszkiel, Gaëlle Noé, Pascaline Boudou-Rouquette, et al.
European Journal of Clinical Pharmacology|March 23, 2023
Predictive factors associated with pemetrexed acute toxicityMathilde Bonnet, Anne Jouinot, Pascaline Boudou-Rouquette, et al.
Cancers|June 5, 2019
Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with NivolumabGaëlle Noé, Audrey Bellesoeur, Lisa Golmard, et al.
Pageof 13

Showing results (31-40 of 122) with videos related to

Sort By:
Pageof 13
Plos One|June 6, 2012
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinomaOlivier Mir, Romain Coriat, Benoit Blanchet, et al.
Cancer Chemotherapy and Pharmacology|August 24, 2023
Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resectionCléa Tardy, Alicja Puszkiel, Pascaline Boudou-Rouquette, et al.
Clinical Medicine (London, England)|August 3, 2021
Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in ParisCamille Tlemsani, Jennifer Arrondeau, Sixtine De Percin, et al.
Investigational New Drugs|November 1, 2016
Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-oldFrederic Bigot, Pascaline Boudou-Rouquette, Jennifer Arrondeau, et al.
The Journal of Nutrition, Health & Aging|March 22, 2024
Prognostic impact of neurocognitive disorders in older patients with cancer: the ELCAPA prospective cohort studyCatherine Conti, Elena Paillaud, Marie Laurent, et al.
Bulletin Du Cancer|April 23, 2025
[Update of the recommendations for the management and treatment of giant cell bone tumors, on behalf of GroupOS]Pascaline Boudou-Rouquette, Frédérique Larousserie, Valérie Dumaine, et al.
International Journal of Molecular Sciences|January 21, 2023
Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment OptionsCamille Tlemsani, Frédérique Larousserie, Sixtine De Percin, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 7, 2017
Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patientsAlicja Puszkiel, Gaëlle Noé, Pascaline Boudou-Rouquette, et al.
European Journal of Clinical Pharmacology|March 23, 2023
Predictive factors associated with pemetrexed acute toxicityMathilde Bonnet, Anne Jouinot, Pascaline Boudou-Rouquette, et al.
Cancers|June 5, 2019
Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with NivolumabGaëlle Noé, Audrey Bellesoeur, Lisa Golmard, et al.
Pageof 13